Identification of Potential Missed Opportunities for Human Papillomavirus (HPV) Vaccination in Women Referred to an Academic Colposcopy Clinic for Evaluation of Abnormal Cervical Cytology

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2016 Feb 4

PMID 26839185

Citations 1

Authors

Benjamin J Dorton

Allison F Vitonis

Sarah Feldman

Affiliations

Soon will be listed here.

Abstract

Objective: To identify possible predictors of missed opportunities for human papillomavirus (HPV) counseling and vaccination prior to presentation at an academic colposcopy clinic.

Materials And Methods: We examined the characteristics of 638 vaccinated and 1,024 unvaccinated age-eligible patients using data from a patient registry of women presenting for colposcopic evaluation between 2/26/2007 and 3/10/2014 who were aged 26 or less at presentation. Demographics, smoking history, pregnancy history, sexually transmitted infections (STIs), sexual history, contraception use, immunosuppression, and medical problems were compared between HPV vaccinated and unvaccinated women. Multivariable logistic regression models included age, race, language, marital status, insurance type, lifetime number of sexual partners, other medical illnesses, number of pregnancies, contraception use, history of STIs, and smoking history to determine predictors of HPV vaccination.

Results: In multivariable analysis, race, marital status, and language were not significantly associated with HPV vaccination. Women with fewer pregnancies were more likely to be vaccinated (p-trend <0 .0001). Vaccinated women were more likely to have other medical illnesses (OR=1.44, 95% CI=1.13-1.83) and be aware of their HPV status (OR=1.75, 95% CI= 1.40-2.18).

Conclusions: In this study, greater number of pregnancies was associated with lower vaccination rates as compared to women who had never been pregnant. Reproductive health visits, such as postpartum and family planning visits, represent an ideal opportunity to educate women about HPV and the importance of vaccination, and should be an area of focus to improve current HPV vaccination rates.

Citing Articles

Evaluating the impact of multilevel evidence-based implementation strategies to enhance provider recommendation on human papillomavirus vaccination rates among an empaneled primary care patient population: a study protocol for a stepped-wedge....

Finney Rutten L, Breitkopf C, St Sauver J, Croghan I, Jacobson D, Wilson P Implement Sci. 2018; 13(1):96.

PMID: 30001723 PMC: 6043954. DOI: 10.1186/s13012-018-0778-x.

References

. Committee opinion no. 588: human papillomavirus vaccination. Obstet Gynecol. 2014; 123(3):712-718. DOI: 10.1097/01.AOG.0000444458.00612.6b. View

Laz T, Rahman M, Berenson A . Human papillomavirus vaccine uptake among 18- to 26-year-old women in the United States: National Health Interview Survey, 2010. Cancer. 2013; 119(7):1386-92. PMC: 3645325. DOI: 10.1002/cncr.27894. View

Joura E, Giuliano A, Iversen O, Bouchard C, Mao C, Mehlsen J . A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8):711-23. DOI: 10.1056/NEJMoa1405044. View

Curtis C, Dorell C, Yankey D, Jeyarajah J, Chesson H, Saraiya M . National human papillomavirus vaccination coverage among adolescents aged 13-17 years-National Immunization Survey--teen, United States, 2011. MMWR Suppl. 2014; 63(2):61-70. View

Wright Jr T, Massad L, Dunton C, Spitzer M, Wilkinson E, Solomon D . 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. Am J Obstet Gynecol. 2007; 197(4):340-5. DOI: 10.1016/j.ajog.2007.07.050. View

Kessels S, Marshall H, Watson M, Braunack-Mayer A, Reuzel R, Tooher R . Factors associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine. 2012; 30(24):3546-56. DOI: 10.1016/j.vaccine.2012.03.063. View

Garland S, Hernandez-Avila M, Wheeler C, Perez G, Harper D, Leodolter S . Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-43. DOI: 10.1056/NEJMoa061760. View

Williams W, Lu P, OHalloran A, Bridges C, Kim D, Pilishvili T . Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. MMWR Morb Mortal Wkly Rep. 2015; 64(4):95-102. PMC: 4584858. View

Tedaldi E, Baker R, Moorman A, Wood K, Fuhrer J, McCabe R . Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis. 2004; 38(10):1478-84. DOI: 10.1086/420740. View

10.

Saslow D, Castle P, Cox J, Davey D, Einstein M, Ferris D . American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57(1):7-28. DOI: 10.3322/canjclin.57.1.7. View

11.

Munoz N, Bosch F, de Sanjose S, Herrero R, Castellsague X, Shah K . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348(6):518-27. DOI: 10.1056/NEJMoa021641. View

12.

Rosenthal S, Weiss T, Zimet G, Ma L, Good M, Vichnin M . Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine. 2010; 29(5):890-5. DOI: 10.1016/j.vaccine.2009.12.063. View

13.

Leddy M, Anderson B, Gall S, Schulkin J . Obstetrician-gynecologists and the HPV vaccine: practice patterns, beliefs, and knowledge. J Pediatr Adolesc Gynecol. 2009; 22(4):239-46. DOI: 10.1016/j.jpag.2008.09.002. View

14.

Massad L, Einstein M, Huh W, Katki H, Kinney W, Schiffman M . 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013; 121(4):829-846. DOI: 10.1097/AOG.0b013e3182883a34. View

15.

Wright Jr T, Massad L, Dunton C, Spitzer M, Wilkinson E, Solomon D . 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197(4):346-55. DOI: 10.1016/j.ajog.2007.07.047. View

16.

Etter D, Zimet G, Rickert V . Human papillomavirus vaccine in adolescent women: a 2012 update. Curr Opin Obstet Gynecol. 2012; 24(5):305-10. DOI: 10.1097/GCO.0b013e3283567005. View

17.

Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J . Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States. MMWR Morb Mortal Wkly Rep. 2014; 63(29):620-4. PMC: 5779422. View

18.

Clifford G, Franceschi S, Diaz M, Munoz N, Villa L . Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24 Suppl 3:S3/26-34. DOI: 10.1016/j.vaccine.2006.05.026. View

19.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

20.

. National and state vaccination coverage among adolescents aged 13 through 17 years--United States, 2010. MMWR Morb Mortal Wkly Rep. 2011; 60(33):1117-23. View